Title:
FUSION PROTEIN INHIBITORS OF KLK5
Document Type and Number:
WIPO Patent Application WO/2024/020083
Kind Code:
A3
Abstract:
Disclosed are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease activity. Pharmaceutical compositions and therapeutic methods using the polypeptides and pharmaceutical compositions are also provided.
Inventors:
BABU YARLAGADDA (US)
CHEN XILIN (US)
CHEN XILIN (US)
Application Number:
PCT/US2023/028123
Publication Date:
March 14, 2024
Filing Date:
July 19, 2023
Export Citation:
Assignee:
BIOCRYST PHARM INC (US)
International Classes:
A61K38/57; C07K14/81; C12N15/11
Domestic Patent References:
| WO2018195472A1 | 2018-10-25 | |||
| WO2021055577A2 | 2021-03-25 |
Attorney, Agent or Firm:
GORDON, Dana, M. et al. (US)
Download PDF:
Previous Patent: VESTIBULAR STIMULATION MEDICAL DEVICE
Next Patent: HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4
Next Patent: HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4